JP2009526552A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009526552A5 JP2009526552A5 JP2008555446A JP2008555446A JP2009526552A5 JP 2009526552 A5 JP2009526552 A5 JP 2009526552A5 JP 2008555446 A JP2008555446 A JP 2008555446A JP 2008555446 A JP2008555446 A JP 2008555446A JP 2009526552 A5 JP2009526552 A5 JP 2009526552A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- relt
- antibody
- hvr
- ifn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 44
- 229940024606 amino acid Drugs 0.000 claims 42
- 235000001014 amino acid Nutrition 0.000 claims 42
- 102000018795 RELT Human genes 0.000 claims 33
- 108010052562 RELT Proteins 0.000 claims 33
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 27
- 210000004027 cell Anatomy 0.000 claims 21
- 239000004471 Glycine Substances 0.000 claims 15
- 238000000034 method Methods 0.000 claims 15
- 235000002374 tyrosine Nutrition 0.000 claims 15
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 15
- 229960004441 tyrosine Drugs 0.000 claims 15
- 102100022297 Integrin alpha-X Human genes 0.000 claims 14
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 14
- 235000003704 aspartic acid Nutrition 0.000 claims 14
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 102000006992 Interferon-alpha Human genes 0.000 claims 13
- 108010047761 Interferon-alpha Proteins 0.000 claims 13
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 13
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 13
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 13
- 235000004400 serine Nutrition 0.000 claims 13
- 229960001153 serine Drugs 0.000 claims 13
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 12
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical group OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 12
- 235000004279 alanine Nutrition 0.000 claims 11
- 229960003767 alanine Drugs 0.000 claims 11
- 229960001230 asparagine Drugs 0.000 claims 11
- 235000009582 asparagine Nutrition 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 230000000694 effects Effects 0.000 claims 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 9
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 9
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 9
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 9
- 239000004474 valine Substances 0.000 claims 9
- 235000014393 valine Nutrition 0.000 claims 9
- 208000024891 symptom Diseases 0.000 claims 8
- 239000004475 Arginine Substances 0.000 claims 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 7
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 7
- 239000004473 Threonine Substances 0.000 claims 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 7
- 235000009697 arginine Nutrition 0.000 claims 7
- 235000006109 methionine Nutrition 0.000 claims 7
- 229930182817 methionine Natural products 0.000 claims 7
- 235000008521 threonine Nutrition 0.000 claims 7
- 229960002898 threonine Drugs 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 5
- 235000013922 glutamic acid Nutrition 0.000 claims 5
- 239000004220 glutamic acid Substances 0.000 claims 5
- 230000005764 inhibitory process Effects 0.000 claims 5
- 230000004936 stimulating effect Effects 0.000 claims 5
- 210000004443 dendritic cell Anatomy 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 4
- 235000014304 histidine Nutrition 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 230000011488 interferon-alpha production Effects 0.000 claims 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 4
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 229960000310 isoleucine Drugs 0.000 claims 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 3
- 235000005772 leucine Nutrition 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 230000002035 prolonged effect Effects 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 235000013930 proline Nutrition 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 101100482072 Homo sapiens RELT gene Proteins 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 102000003945 NF-kappa B Human genes 0.000 claims 1
- 108010057466 NF-kappa B Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- -1 aspartic acid Amino acid Chemical class 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77291106P | 2006-02-13 | 2006-02-13 | |
| PCT/US2007/061988 WO2007117763A2 (en) | 2006-02-13 | 2007-02-12 | Methods and compositions for targeting relt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009526552A JP2009526552A (ja) | 2009-07-23 |
| JP2009526552A5 true JP2009526552A5 (https=) | 2010-03-11 |
Family
ID=38581714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008555446A Pending JP2009526552A (ja) | 2006-02-13 | 2007-02-12 | Ｒｅｌｔをターゲッティングするための方法と組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20080057066A1 (https=) |
| EP (1) | EP1984404A2 (https=) |
| JP (1) | JP2009526552A (https=) |
| KR (1) | KR20080099264A (https=) |
| CN (1) | CN101432306A (https=) |
| AR (1) | AR059447A1 (https=) |
| AU (1) | AU2007235213A1 (https=) |
| BR (1) | BRPI0706868A2 (https=) |
| CA (1) | CA2638865A1 (https=) |
| CR (1) | CR10201A (https=) |
| EC (1) | ECSP088675A (https=) |
| IL (1) | IL192957A0 (https=) |
| MA (1) | MA30265B1 (https=) |
| NO (1) | NO20083609L (https=) |
| RU (1) | RU2008136864A (https=) |
| TW (1) | TW200804418A (https=) |
| WO (1) | WO2007117763A2 (https=) |
| ZA (1) | ZA200806448B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011022335A1 (en) * | 2009-08-21 | 2011-02-24 | Mount Sinai School Of Medicine Of New York University | Methods of using cd44 fusion proteins to treat cancer |
| US20130225503A1 (en) * | 2009-09-30 | 2013-08-29 | Baylor Licnensing Group | Tex14 peptides as novel antitumor agents |
| US20130338080A1 (en) * | 2012-05-24 | 2013-12-19 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating an activated b-cell diffuse large b-cell lymphoma |
| KR101966246B1 (ko) * | 2015-11-17 | 2019-04-05 | 서울대학교산학협력단 | FCHo1 조절제를 포함하는 세포 분열 조절용 조성물 및 이를 이용한 세포 분열 조절 방법 |
| CA3055200A1 (en) * | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Compositions and methods for immunotherapy |
| WO2021231405A1 (en) * | 2020-05-12 | 2021-11-18 | Board Of Regents, The University Of Texas System | Methods for treating glioblastoma |
| CN114209843A (zh) * | 2022-01-21 | 2022-03-22 | 华中科技大学同济医学院附属同济医院 | 与relt信号通路有关的抑制剂/激活剂及其应用 |
| CN117362438B (zh) * | 2023-08-30 | 2024-04-30 | 华中科技大学同济医学院附属同济医院 | 一种抗relt重组单克隆抗体及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| JP2003052374A (ja) * | 2001-08-10 | 2003-02-25 | Kirin Brewery Co Ltd | 新規樹状細胞膜分子及びそれをコードするｄｎａ |
| EP2572714A1 (en) * | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
| EP2784084B2 (en) * | 2003-07-08 | 2023-10-04 | Novartis Pharma AG | Antagonist antibodies to IL-17A/F heterologous polypeptides |
| KR20070010046A (ko) * | 2004-04-06 | 2007-01-19 | 제넨테크, 인크. | Ｄｒ5 항체 및 그의 용도 |
-
2007
- 2007-02-12 ZA ZA200806448A patent/ZA200806448B/xx unknown
- 2007-02-12 CA CA002638865A patent/CA2638865A1/en not_active Abandoned
- 2007-02-12 EP EP07797130A patent/EP1984404A2/en not_active Withdrawn
- 2007-02-12 KR KR1020087019599A patent/KR20080099264A/ko not_active Withdrawn
- 2007-02-12 US US11/674,074 patent/US20080057066A1/en not_active Abandoned
- 2007-02-12 JP JP2008555446A patent/JP2009526552A/ja active Pending
- 2007-02-12 BR BRPI0706868-9A patent/BRPI0706868A2/pt not_active IP Right Cessation
- 2007-02-12 AR ARP070100582A patent/AR059447A1/es unknown
- 2007-02-12 AU AU2007235213A patent/AU2007235213A1/en not_active Abandoned
- 2007-02-12 CN CNA2007800133798A patent/CN101432306A/zh active Pending
- 2007-02-12 WO PCT/US2007/061988 patent/WO2007117763A2/en not_active Ceased
- 2007-02-12 RU RU2008136864/13A patent/RU2008136864A/ru unknown
- 2007-02-13 TW TW096105340A patent/TW200804418A/zh unknown
-
2008
- 2008-07-22 IL IL192957A patent/IL192957A0/en unknown
- 2008-08-12 CR CR10201A patent/CR10201A/es not_active Application Discontinuation
- 2008-08-12 EC EC2008008675A patent/ECSP088675A/es unknown
- 2008-08-20 NO NO20083609A patent/NO20083609L/no not_active Application Discontinuation
- 2008-09-08 MA MA31215A patent/MA30265B1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009526552A5 (https=) | ||
| US20240368261A1 (en) | Compositions and methods for growth factor modulation | |
| RU2008136864A (ru) | Способы и композиции для нацеливания на relt | |
| WO2015032932A1 (en) | Il-18 binding protein (il-18bp) in inflammatory diseases | |
| EP3735260B1 (en) | Therapeutic peptides and methods for treating autoimmune related disease | |
| JP7822577B2 (ja) | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 | |
| JP2011511624A5 (https=) | ||
| US20210009677A1 (en) | Method of treating asthma | |
| CA2443345A1 (en) | Disease-associated protein | |
| WO2023180503A1 (en) | Methods for reducing respiratory infections | |
| GB2493313A (en) | Kissorphin peptides for use in the treatment of alzheimer's disease, creutzfeldtjakob disease or diabetes mellitus | |
| WO2016129005A1 (en) | Thymosin alpha 1 for use in treatment of cystic fibrosis | |
| CN108948203A (zh) | 抗pd-1单克隆抗体及其制备方法和应用 | |
| EP4161576A1 (en) | Method of treating or preventing acute respiratory distress syndrome | |
| US20250145994A1 (en) | Compositions and methods for treating conditions related to cellular senescence | |
| CN113874030A (zh) | Ards的治疗 | |
| US20230416381A1 (en) | Methods for treating or preventing acute respiratory distress syndrome | |
| US11421025B2 (en) | Treatment of IL-17A diseases | |
| WO2024053742A1 (ja) | コロナウイルス感染症の治療薬 | |
| WO2021243185A9 (en) | Sars-cov-2 binding agents and uses thereof | |
| CN117062609A (zh) | 用于治疗或预防急性呼吸窘迫综合征的方法 | |
| CN117255692A (zh) | Trem2激动剂生物标志物和其使用方法 | |
| CN119654344A (zh) | 抗siglec15抗体及其用途 | |
| HK40048816A (en) | Compositions and methods for growth factor modulation | |
| CN118742563A (zh) | 靶向usag-1分子的用于牙齿再生治疗的中和抗体 |